Clinical trials: Staphylococcal Infections
Staphylococcus Aureus Infection
Nasal Decolonization of Dialysis Patients Noses
Hemodialysis patients are at high-risk for infections, specifically Staphylococcus aureus infections. The investigators propose to 1) implement a novel intervention (nasal povidone-iodine at each hemodialysis session) to prevent…
- Trial name
- PAINTS (NCT04210505)
- Testing
- Povidone-Iodine Topical Ointment, Standard Care
- Where
- 5 sites in United States
- Volunteers
- 302 people
- Sponsor
- Marin L. Schweizer, PhD
Staphylococcal Infections
Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients' Clinical Outcome in Orthopedic Device Related Bone Infections
This was a prospective study performed between November 2011 and September 2013. Patients with a confirmed S. aureus infection after fracture fixation or prosthetic joint infection were included.
- Trial name
- StaphType (NCT02971657)
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- BG Unfallklinik Murnau
Infective Endocarditis, Infection Staphylococcal
NExt-Generation Sequencing and Cell Culture-based Characterization of S. Aureus in Infective Endocarditis
Infective endocarditis is a deadly disease with a mortality rate between 20 and 40%. Antibiotic therapy is of utmost importance. It is primarily guided by microbial results from positive blood culture.
- Trial name
- NESSIE (NCT04257292)
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Jena University Hospital
Staphylococcal Infection, Abscess
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).
- Conditions
- Staphylococcal Infection, Abscess, Staphylococcal Skin Infection, Folliculitis
- Trial name
- NCT00352612
- Testing
- clindamycin, cephalexin
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Aaron Chen
Staphylococcal Aureus Infection, Staphylococcus Aureus Bacteraemia
Subphenotype- and Complication-guided Adjunctive Fosfomycin Therapy for Staphylococcus Aureus Bacteraemia
Staphylococcus aureus bacteraemia (SAB) is a major global cause of sepsis-related mortality. Randomised trials of adjunctive antibiotics, including fosfomycin, have not shown consistent benefit, possibly due to inclusion of…
- Trial name
- NCT07155590
- Where
- 2 sites in Spain
- Volunteers
- 369 people
- Sponsor
- Hospital Universitari de Bellvitge
Staphylococcus Aureus
Mupirocin-Iodophor ICU Decolonization Swap Out Trial
The Swap Out Trial is a cluster randomized controlled trial of HCA hospitals, evaluating the non-inferiority of two decolonization regimens: Arm 1 Routine Care: ICU nasal decolonization with mupirocin twice daily for 5 days in…
- Trial name
- NCT03140423
- Testing
- Arm 1. Routine Care (Mupirocin/CHG), Arm 2. Iodophor/CHG Decolonization
- Where
- 137 sites in United States
- Volunteers
- 353,323 people
- Sponsor
- Harvard Pilgrim Health Care
Endocarditis, Bacterial, Infective Endocarditis
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
The overall goals of this study are to compare the safety and efficacy of daptomycin monotherapy 10 mg/kg/day and vancomycin monotherapy dosed to achieve vancomycin trough levels of 15 to 20 μg/mL for the treatment of…
- Trial name
- HDSAB (NCT00695903)
- Testing
- daptomycin, vancomycin
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcal Infection
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
The objective of this trial is 1) to evaluate the safety and clinical acceptability of a 5-day course of mupirocin applied every 8 hours (± 2 hours) to the nares, umbilical and perianal areas of infants residing in the ICU.
- Trial name
- NCT01827358
- Testing
- Mupirocin calcium
- Where
- 6 sites in United States
- Volunteers
- 155 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Staphylococcus
Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU
The purpose of this study is to determine whether or not mupirocin treatment results in S. aureus decolonization in affected NICU patients.
- Trial name
- NCT02967432
- Testing
- Mupirocin Topical Ointment, Petroleum Jelly
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- Crouse Hospital
Skin Diseases, Infectious, Skin Diseases, Bacterial
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections.
- Conditions
- Skin Diseases, Infectious, Skin Diseases, Bacterial, Staphylococcal Skin Infections
- Trial name
- NCT00210899
- Testing
- ceftobiprole medocaril, Vancomycin plus Ceftazidime
- Volunteers
- 828 people
- Sponsor
- Basilea Pharmaceutica
Scabies, Yaws
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
This is an open-label prospective community intervention trial to assess the impact of community mass treatment with azithromycin for yaws and ivermectin for scabies, on non-yaws bacterial skin infections.
- Conditions
- Scabies, Yaws, Impetigo
- Trial name
- AIM-Skin (NCT02775617)
- Testing
- Ivermectin, Azithromycin, Permethrin
- Where
- Solomon Islands
- Volunteers
- 1,291 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Staph Aureus Colonization, Staph Aureus Infection
Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial
This trial will test the hypothesis that treating parents of neonates requiring NICU care with intranasal mupirocin and topical chlorhexidine bathing will reduce the spread of S. aureus from parents to neonates.
- Trial name
- TREAT PARENTS (NCT02223520)
- Testing
- Mupirocin and Chlorhexidine
- Where
- 2 sites in United States
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Secondarily Infected Traumatic Lesions (SITL), Impetigo
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
A national, prospective single arm phase II study investigating the pharmacokinetics and safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with impetigo or Secondarily Infected Traumatic…
- Trial name
- NCT00758862
- Testing
- 2% TD1414 Cream
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- LEO Pharma
Staphylococcus Aureus Infection
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus…
- Trial name
- NCT02282605
- Testing
- XF-73 nasal gel, Chlorhexidine gluconate 2% topical cloths
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Destiny Pharma Plc
Methicillin Resistant Staphylococcus Aureus (MRSA)
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects.
- Trial name
- ZEPHYR (NCT00084266)
- Testing
- linezolid (Zyvox), vancomycin
- Where
- 177 sites in United States, Argentina and 20 more
- Volunteers
- 1,225 people
- Sponsor
- Pfizer
Staphylococcus Aureus
Antimicrobial Drug Use and Resistant Staphylococcus Aureus
The purpose of this investigation is to study the relationships between antimicrobial stewardship program efforts, antimicrobial drug use, and infection control efforts to the incidence rates of hospital acquired infections with…
- Trial name
- NCT01075451
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Virginia Commonwealth University
Staphylococcus Aureus Infection
A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)
This is a study to evaluate the safety and immunogenicity of V710 with and without Merck Aluminum Adjuvant (MAA) in adult participants with end-stage kidney disease who are on hemodialysis.
- Trial name
- NCT00572910
- Volunteers
- 206 people
- Sponsor
- Merck Sharp & Dohme LLC
Staphylococcus Aureus
Impact of 18 FDG PET/CT on the Management of Patients With Staphylococcus Aureus Bloodstream Infection
S. aureus bloodstream infection (SAB) is a severe disease associated with a 30% case-fatality rate at 12 weeks. Severity of this disease is related to the high prevalence of staphylococcal Deep Foci of Infection (SA-DFI), which…
- Trial name
- TEPSTAR (NCT03419221)
- Testing
- PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions, Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
- Where
- France
- Volunteers
- 291 people
- Sponsor
- University Hospital, Montpellier
Healthy, Staphylococcus Aureus Infection
Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study
Mupirocin is an old antibiotic used topically since the 1970s. Initially used in the treatment of skin infections for its antistaphylococcal action, it is now part of the decolonization strategy for Staphylococcus aureus (SA)…
- Trial name
- MUPIPHARM (NCT06368856)
- Testing
- Mupirocin (50 mg), Mupirocin (500 mg), blood samples after Single dose part
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Pneumonia, Staphylococcal
Vancomycin Dosage Strategy Based on a Trough Concentration Model
Study design: Allocation: Randomized Endpoint classification: Efficacy study Masking: Open label Primary purpose: Treatment Primary endpoint: Incidence of reaching the target serum trough concentration Secondary endpoint…
- Trial name
- NCT04088305
- Testing
- Individualized therapy
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University Third Hospital